Zonisamide attenuates MPTP neurotoxicity in marmosets

J Pharmacol Sci. 2010;114(3):298-303. doi: 10.1254/jphs.10120fp. Epub 2010 Oct 8.

Abstract

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces parkinsonism in humans and animals. The effects of zonisamide on dopamine neurons were studied in MPTP-treated common marmosets (Callithrix jacchus). Groups of animals (n = 3) were treated with MPTP (2.5 mg/kg, every 24 h x 3); MPTP plus zonisamide (40 mg/kg administered 1 h before each MPTP dose); MPTP plus selegiline (a known MAO-B inhibitor) (2 mg/kg administered 1 h before each MPTP dose); and saline controls. An immunohistochemical study of the substantia nigra was performed 14 days after MPTP treatment in each group. MPTP reduced the mean number of tyrosine hydroxylase (TH)-positive neurons to 10% of the normal control group and mean cell size was significantly (P < 0.001) reduced from 424 to 159 µm². In the group pre-treated with zonisamide, the mean number of TH-positive neurons was reduced to 26% of that in the normal control group and the mean neuron size was significantly (P < 0.05) increased from 159 to 273 µm² compared with the group treated with MPTP alone. Moreover, in the group pre-treated with selegiline, the mean number of TH-positive neurons was 47% of that in the normal control group and the mean neuron size was increased significantly (P < 0.01) from 159 to 319 µm² compared to the group treated with MPTP alone. This observation suggests that zonisamide reduces MPTP toxicity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Callithrix
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dopamine / pharmacology
  • Female
  • Humans
  • Isoxazoles / pharmacology*
  • MPTP Poisoning / drug therapy*
  • MPTP Poisoning / metabolism
  • Male
  • Neostriatum / drug effects
  • Neostriatum / metabolism
  • Neurons / drug effects
  • Neurons / metabolism
  • Neuroprotective Agents / pharmacology
  • Neurotoxins / toxicity
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / metabolism
  • Selegiline / pharmacology
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism
  • Tyrosine 3-Monooxygenase / metabolism*
  • Zonisamide

Substances

  • Antiparkinson Agents
  • Isoxazoles
  • Neuroprotective Agents
  • Neurotoxins
  • Selegiline
  • Zonisamide
  • Tyrosine 3-Monooxygenase
  • Dopamine